134 related articles for article (PubMed ID: 10780572)
1. Rab11 in dysplasia of Barrett's epithelia.
Goldenring JR; Ray GS; Lee JR
Yale J Biol Med; 1999; 72(2-3):113-20. PubMed ID: 10780572
[TBL] [Abstract][Full Text] [Related]
2. Increased immunoreactivity for Rab11, a small GTP-binding protein, in low-grade dysplastic Barrett's epithelia.
Ray GS; Lee JR; Nwokeji K; Mills LR; Goldenring JR
Lab Invest; 1997 Nov; 77(5):503-11. PubMed ID: 9389793
[TBL] [Abstract][Full Text] [Related]
3. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
4. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
7. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
8. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
[TBL] [Abstract][Full Text] [Related]
9. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
10. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.
Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH
Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
13. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
14. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
Goldblum JR; Lauwers GY
Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
[TBL] [Abstract][Full Text] [Related]
16. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
17. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
Cameron AJ; Carpenter HA
Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
19. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
Younes M; Lebovitz RM; Lechago LV; Lechago J
Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
[TBL] [Abstract][Full Text] [Related]
20. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
